Mono-amine oxidase inhibitors and schizophrenia.
D000208:Acute Disease; D000588:Amines / Q000652:urine*; D000661:Amphetamine / Q000009:adverse effects; D002908:Chronic Disease; D006213:Hallucinogens / Q000652:urine; D006801:Humans; D007490:Iproniazid / Q000009:adverse effects; D007538:Isoniazid / Q000009:adverse effects; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D010293:Pargyline / Q000009:adverse effects; D011605:Psychoses, Substance-Induced; D012559:Schizophrenia / Q000188:drug therapy* / Q000652:urine*
D000588:Amines; D006213:Hallucinogens; D008996:Monoamine Oxidase Inhibitors; D010293:Pargyline; D000661:Amphetamine; D007490:Iproniazid; D007538:Isoniazid